文献速递衰弱、肌少症与跌倒老年慢病共病管理

COVID-19疫苗在老年人群中的有效性与安全性

Efficacy and safety of COVID-19 vaccines in older people.
PubMed 文献 · Age Ageing · 2021-01-01

本文综述了多种候选COVID-19疫苗在老年人群中的安全性和有效性证据。II期试验显示健康老年人抗体反应和轻中度不良事件均较年轻受试者有所减少,但合并症和衰弱老年人被大多数试验排除,缺乏已发表的安全性和有效性数据。尽管证据有限,衰弱老年人仍应优先接种疫苗。

要点

  • 健康老年人II期试验显示抗体反应和轻中度不良事件较年轻受试者减少。
  • 合并症和衰弱老年人被大多数试验排除,缺乏已发表的安全性和有效性数据。
  • 衰弱老年人应优先接种疫苗,但需基于有限证据做出接种决策。

核心结论

  • 健康老年人接种COVID-19疫苗的抗体反应和轻中度不良事件较年轻受试者有所减少。
  • 合并症和衰弱老年人被大多数试验排除,缺乏已发表的安全性和有效性数据。
  • 尽管证据有限,衰弱老年人仍应优先接种疫苗,接种决策需基于现有有限证据。

研究设计与样本

  • 本文为综述,聚焦于可能获批的主要候选COVID-19疫苗在老年人群中安全性和有效性的证据。

主要发现

  • 多个II期试验显示健康老年人抗体反应较强且安全性良好,但除阿斯利康疫苗外招募老年人较少。
  • 来自II期试验的稀疏数据提示健康老年人抗体反应和轻中度不良事件均较年轻受试者减少。
  • Pfizer和Moderna疫苗的III期试验中期分析通过新闻稿宣布了高效力,但合并症和衰弱老年人仍被大量排除。
  • 目前尚无合并症和衰弱老年人接种COVID-19疫苗的安全性和有效性已发表数据。

临床怎么用

  • 衰弱老年人应优先接种COVID-19疫苗。
  • 患者、照护者和监督医疗专业人员需基于有限证据做出接种决策。

局限性

  • 合并症和衰弱老年人被大多数临床试验排除,缺乏该人群的安全性和有效性已发表数据。
  • 除阿斯利康疫苗外,II期试验招募老年人较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several vaccines against coronavirus disease 2019 (COVID-19) are on the cusp of regulatory approval. Their safety and efficacy in older people is critical to their success. Even though care home residents and older people are likely to be amongst the first to be vaccinated, these patient groups are usually excluded from clinical trials. Data from several Phase II trials have given cause for optimism, with strong antibody responses and reassuring safety profiles but, with the exception of AstraZeneca's vaccine, recruited few older people. Overall, the sparse data from Phase II trials suggest a reduction in both antibody responses and mild to moderate adverse events in well older people compared to younger participants. Many of the Phase III trials have made a conscious effort to recruit older people, and interim analyses of the Pfizer and Moderna vaccine have led to press releases announcing high degrees of efficacy. However, older people with co-morbidities and frailty have once again been largely excluded and there are no published data on safety and efficacy in this group. Although the speed and impact of the pandemic on older people with frailty justify an approach where they are offered vaccination first, patients and their carers and supervising health care professionals alike will need to make a decision on accepting vaccination based on limited evidence. Here we review the main candidate vaccines that may become available, with a focus on the evidence of safety and efficacy in older people.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Soiza RL, Scicluna C, Thomson EC, et al. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021. PMID: 33320183. doi:10.1093/ageing/afaa274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。